Seminal plasma concentrations of long-acting cabotegravir in men receiving HIV pre-exposure prophylaxis
To address the lack of data on male genital tract penetration of CAB-LA PrEP, seminal plasma was collected at days 3, 7, 28, 84, and 140 and analyzed by LC-MS/MS. CAB was detectable in 71% of samples at day 3, 73% at day 7, and 92% at day 28, with all samples quantifiable at days 84 and 140. Seminal-to-blood plasma ratios remained low but proportional to systemic exposure, indicating sustained seminal CAB exposure.
Authors
- Davide Moschese (ORCID: https://orcid.org/0000-0001-5901-6742)
- Samuel Lazzarin (ORCID: https://orcid.org/0009-0007-9174-2091)
- Francesco Petri (ORCID: https://orcid.org/0000-0003-0125-9551)
- Andrea Giacomelli (ORCID: https://orcid.org/0000-0003-3685-4289)
- D Maddalena
- Francesco Caruso (ORCID: https://orcid.org/0000-0002-9665-9234)
- Maria Vittoria Cossu (ORCID: https://orcid.org/0000-0002-6984-3028)
- Cristina Gervasoni (ORCID: https://orcid.org/0000-0002-4922-6495)
- Dario Cattaneo
- Valentina Mazzotta
- Chiara Fusetti
- Andrea Gori
- Andrea Antinori
- Antonio D’Avolio
Institutions
- Humanitas University (IT)
- University of Milan (IT)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Ospedale Amedeo di Savoia (IT)
- Centre for Multidisciplinary Research in Health Science (IT)
- ASST Fatebenefratelli Sacco (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1128/aac.00165-26
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- ViiV Healthcare
- Bavarian Nordic
- Cilag